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Background: Cerium oxide (CeO
2
) nanoparticles have been posited to have both beneficial 
and toxic effects on biological systems. Herein, we examine if a single intratracheal instillation 
of CeO
2
 nanoparticles is associated with systemic toxicity in male Sprague-Dawley rats.
Methods and results: Compared with control animals, CeO
2
 nanoparticle exposure was 
associated with increased liver ceria levels, elevations in serum alanine transaminase levels, 
reduced albumin levels, a diminished sodium-potassium ratio, and decreased serum triglyceride 
levels (P , 0.05). Consistent with these data, rats exposed to CeO
2
 nanoparticles also exhibited 
reductions in liver weight (P , 0.05) and dose-dependent hydropic degeneration, hepatocyte 
enlargement, sinusoidal dilatation, and accumulation of granular material. No histopathologi-
cal alterations were observed in the kidney, spleen, and heart. Analysis of serum biomarkers 
suggested an elevation of acute phase reactants and markers of hepatocyte injury in the rats 
exposed to CeO
2
 nanoparticles.
Conclusion: Taken together, these data suggest that intratracheal instillation of CeO
2
 
 nanoparticles can result in liver damage.
Keywords: cerium oxide nanoparticles, systemic toxicity, hepatic toxicity, hydropic 
degeneration
Introduction
Cerium is a rare earth lanthanide metal and a strong oxidizing agent. Cerium exists 
both in the trivalent state (Ce3+, cerous) and very stable tetravalent state (Ce4+, ceric) 
as cerium oxide (CeO
2
).1 CeO
2
 is widely used as a polishing agent for glass mirrors, 
television tubes, and ophthalmic lenses.2 In addition, CeO
2
 can also act as a catalyst 
because it can both accept and donate oxygen.3 This latter property has led to the wide-
spread use of CeO
2
 in the automobile industry, where it has been used to increase fuel 
efficiency and reduce particulate emissions.4–6 It appears that CeO
2
 nanoparticles may 
also be capable of acting as antioxidants, which has led some to postulate that these 
particles may be useful for the treatment of cardiovascular disease,7 neurodegenerative 
disease,8 and radiation-induced tissue damage.9,10 Nonetheless, other in vitro work has 
shown that CeO
2
 nanoparticles can also cause oxidative stress.11
The Organization for Economic Co-operation and Development Working Party 
on Manufactured Nanomaterials has demarcated CeO
2
 nanoparticles along with 
14 other nanoparticles as a high-priority for evaluation.12 Given current industrial 
applications, it is thought that the most common route of CeO
2
 exposure is likely to 
be through inhalation and/or ingestion. Although previous studies have shown that 
intratracheal instillation of CeO
2
 nanoparticles can cause a toxicological response 
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in the lung, whether these particles also exhibit systemic 
toxicity is currently unclear.2,13 Therefore, the purpose of the 
current study was to determine if the intratracheal instillation 
of CeO
2
 nanoparticles is associated with alterations in the 
indices of systemic toxicity and pathological change. On the 
basis of previous work examining the translocation of carbon 
nanotubes from the lung,14 we hypothesized that intratracheal 
instillation of CeO
2
 nanoparticles could lead to nanoparticle 
deposition in other organs through the circulation. Consistent 
with this hypothesis, our data suggest that the intratracheal 
instillation of CeO
2
 nanoparticles is associated with increased 
liver ceria levels, reductions in liver weight, and evidence of 
liver damage.
Materials and methods
Particle characterization
CeO
2
 nanoparticles, 10 wt% in water (average diameter 
approximately 20 nm), were obtained from Sigma-Aldrich 
(St Louis, MO) as previously outlined.13 Normal saline 
was used as vehicle to suspend the nanoparticles prior to 
 instillation. CeO
2
 samples diluted in saline were used for ani-
mal exposures. Since the CeO
2
 nanoparticles form agglomer-
ates in suspension, the size distribution of the agglomerates 
of CeO
2
 was analyzed using field emission scanning electron 
microscopy and transmission electron microscopy (TEM).
The CeO
2
 suspension was analyzed using field emission 
scanning electron microscopy as follows: the CeO
2
 particle 
suspensions were diluted with distilled water (about 10-fold) 
and were dried on carbon planchet and sputter-coated. After 
sputter-coating, the specimens were examined with a Hitachi 
Model S-4800 field emission scanning electron microscope 
(Schaumburg, IL) between 5 kV and 20 kV. In addition, the 
particles were diluted in double distilled filtered water and a 
drop was placed on a formvar-coated copper grid to dry before 
viewing the samples with a JEOL 1220 TEM (Tokyo, Japan).
Animal handling and instillation  
of CeO2 nanoparticles
Specific pathogen-free male Sprague-Dawley (Hla: SD-CVF) 
rats (6 weeks old) were purchased from Hilltop Laboratories 
(Scottdale, PA). Rats were kept in cages individually and 
ventilated with HEPA filtered air in an animal facility accred-
ited by the Association for Assessment and Accreditation of 
Laboratory Animal Care International. After acclimatization 
for one week, the rats were randomly divided into four groups 
(n = 7 per group) to receive vehicle control (saline, 0.9% NaCl), 
or instillation of 1.0, 3.5, or 7.0 mg/kg CeO
2
 nanoparticles. 
Rats were anesthetized with sodium methohexital (35 mg/kg, 
intraperitoneally) and placed on an inclined restraint board 
before instillation with 0.3 mL of saline suspension or CeO
2
 
nanoparticles. The animals were euthanized 28 days post-
exposure by drug overdose according to the Guide for the 
Care and Use of Laboratory Animals and as approved by the 
National Institute for Occupational Safety and Health Animal 
Care and Use Committee. All animals were humanely treated 
and were monitored for any potential suffering.
Determination of cerium content  
in the liver
Liver cerium content was estimated by induction coupled 
plasma-mass spectrometry (ICP-MS) at Elemental Analysis 
Inc (Lexington, KY) according to the standard protocol.14 
Briefly, liver samples (n = 4 for each group) were prepared 
using Environmental Protection Agency method 3050B for 
the analysis of total cerium by ICP-MS. A 2.5 g sample was 
weighed to the nearest 0.0001 g and digested with concen-
trated nitric acid, 30% hydrogen peroxide, and concentrated 
hydrochloric acid. A method blank, laboratory control 
sample, a laboratory duplicate, and a predigestion matrix 
spike were prepared for each sample. After digestion, the 
extracts and the quality control samples were diluted to a 
final volume of 50 mL before analysis using an Agilent 
7500cx ICP-MS. The instrument was calibrated for Ce-140 
with 0, 0.1, 1.0, 10.0, and 100 µg/L standards prepared from 
a certified reference standard traceable to National Institute 
of Standards and Technology reference materials. A second 
source calibration verification standard traceable to National 
Institute of Standards and Technology reference materials 
was analyzed to verify the calibration standards. A continuing 
calibration verification standard and a continuing calibration 
blank were analyzed at the beginning of the run, after every 
ten samples, and at the conclusion of the run.
Serum biochemical and lipid  
profile analysis
Blood was collected by cardiac puncture into a serum collec-
tion tube (BD Vacutainer®) before centrifugation at 800× g 
for 15 minutes. Serum was collected and used for biochemical 
assays using an Abaxis VetScan® analyzer (Abaxis, Union 
City, CA). Serum biochemical parameters, ie, alanine ami-
notransferase, alkaline phosphatase, bilirubin, blood urea 
nitrogen, albumin, calcium (Ca2+), creatinine, amylase, 
globulin, potassium (K+), sodium (Na+), phosphorus, total 
bilirubin, and total protein were evaluated with a Compre-
hensive Diagnostic Profile Disk. The lipid profile, ie, total 
cholesterol, triglycerides, and high-density lipoprotein was 
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measured using lipid profile-Glu cassettes (Cholestech LDX) 
and a Cholestech LDX® analyzer. The remaining serum was 
stored at -80°C.
Multiplexed serum protein immunoassays
Pooled serum samples from all seven animals in each 
experimental group were shipped on dry ice to Rules-Based 
Medicine (Austin, TX) for Rodent MAP® version 2.0 anti-
gen analysis using a Luminex 100 instrument, as detailed 
elsewhere.14 The antigen panel consisted of 59 proteins, 
which included proteins involved in inflammation, cytokines, 
growth factors, and tissue factors. Each analyte was quanti-
fied using 4 and 5 parameter, weighted and nonweighted 
curve fitting algorithms using proprietary data analysis 
software developed at Rules-Based Medicine.
Tissue collection and histopathological 
examination
Liver, kidney, spleen, and heart were collected at the 
time of death. Each tissue was weighed and then fixed in 
FineFIX™ (Milestone medicals, Shelton, CT) preserva-
tive for later histopathological examination. Tissues from 
liver, spleen,  kidney, and heart were embedded in paraffin 
wax, sectioned at 5 µm, mounted on glass slide and stained 
with hematoxylin-eosin using standard histopathological 
 techniques. Sections were examined by light microscopy in 
a blinded fashion by a board certified pathologist.
Data analysis
Results are presented as the mean ± standard error of the 
mean. Data were analyzed using the SigmaPlot 11.0 statisti-
cal program. One-way analysis of variance was performed 
for overall comparisons, while the Student–Newman–Keuls 
post hoc test was used to determine differences between 
groups. Values of P , 0.05 were considered to be statisti-
cally significant.
Results
Nanoparticle characterization
Similar to previous work using the same batch of CeO
2
 
nanoparticles,13 analysis of nanoparticle size by TEM and 
scanning electron microscopy confirmed the presence of 
single and agglomerated CeO
2
 nanoparticles in the suspen-
sions (Figure 1A and B). Field emission scanning electron 
microscopy showed that the CeO
2
 nano particles were 
generally dispersed into submicron groups with an average 
size of 9.26 ± 0.58 nm. The diameter of the primary CeO
2
 
particles was determined to be 10.14 ± 0.76 nm by TEM.
CeO2 instillation decreases  
liver wet weight
CeO
2
 instillation at the 1, 3.5, or 7 mg/kg dosages had no 
significant effect on rat body, heart, kidney, or spleen weight 
(Table 1). Compared with control animals, only the high-
est CeO
2
 dosage (7 mg/kg) decreased liver weight (saline 
control 14.55 ± 0.27 versus CeO
2
 7.0 mg/kg 12.50 ± 0.54; 
P , 0.05, Table 1).
CeO2 instillation increases  
liver ceria content
The ceria content of animals instilled with 7.0 mg/kg CeO
2
 
nanoparticles was higher than that observed in the other 
groups (saline control nondetectable versus 1.0 mg/kg CeO
2
: 
0.05 ± 0.01 ppm versus 3.5 mg/kg CeO
2
: 0.11 ± 0.02 ppm  versus 
CeO
2
 7.0 mg/kg: 0.50 ± 0.18 ppm; P , 0.05; Figure 2).
Effect of CeO2 instillation  
on serum biochemical profile
Table 2 shows the alterations of the serum biochemical param-
eters following CeO
2
 nanoparticle exposure. Compared with 
control animals, CeO
2
 instillation at 1, 3.5, or 7 mg/kg dimin-
ished the sodium to potassium ratio (P , 0.05), while the CeO
2
 
dosage of 7 mg/kg increased serum alanine aminotransferase 
levels and reduced albumin levels (P , 0.05). The serum lipid 
profile analysis (Table 2B) indicated a reduction in the triglyc-
eride levels with 7 mg/kg CeO
2
 nanoparticle exposure.
CeO2 nanoparticle exposure is associated 
with evidence of liver pathology
The primary alterations considered for liver tissue damage 
were hydropic degeneration of the hepatocytes, dilation 
of the sinusoids, portal inflammation, and fibrosis of the 
liver compared to tissues obtained from control animals. 
CeO
2
 nanoparticle exposure showed widespread hydropic 
Figure 1 Characterization of the cerium oxide nanoparticles by (A) field 
emission scanning electron microscopy and (B) transmission electron microscopy 
(scale bar = 200 nm) of a dilute cerium oxide suspension.
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degeneration of hepatocytes around the central vein region 
with sparing of the immediate periportal region (Figure 3). 
These changes were panlobular in nature. Along with 
hydropic degeneration, we also observed enlargement of the 
hepatocytes, enlargement of the nucleus in the hepatocyte, 
binucleation of some hepatocytes, dilatation of the sinusoids, 
and occasional focal inflammation areas in a few of the 
exposed animals ( Figure 4). As the dose of the nanoparticles 
was increased, the number of hepatocytes that show hydropic 
degeneration was also elevated suggesting that changes in 
hepatocyte structure were dose-dependent.
CeO2 nanoparticle exposure does not 
appear to affect spleen, kidney, and heart
Alterations considered for the kidney pathologies were 
necrosis of the proximal tubular epithelium, tubular accumu-
lation of proteinaceous material, and inflammatory reaction 
in the interstitial areas of the cortex and medulla. Spleen 
and heart tissues were examined for any histological altera-
tions in structure along with the infiltration of inflammatory 
cells. We did not observe any alterations in the histological 
appearance or the infiltration of inflammatory cells in the 
kidney, spleen, and heart with CeO
2
 nanoparticle exposure 
(Figures 5–7).
Effect of CeO2 instillation  
on serum protein expression
A panel of 59 protein biomarkers comprising cytokines, 
inflammatory markers, growth factors, and tissue factors 
were quantified in the serum samples collected in this study 
using the RBM RodentMAP® V2.0 multiplex immune assay 
service. Compared with levels observed in the control ani-
mals, the levels of 16 different analytes appeared to exhibit 
a trend towards being increased or decreased by at least 15% 
or more following the instillation procedure with the CeO
2
 
nanoparticles (Figure 8A, B, and C). At the 7.0 mg/kg CeO
2
 
dosage, ten of the analytes (fibroblast growth factor-basic, 
haptoglobin, immunoglobulin A, interleukin-11, matrix met-
alloproteinase-9, myoglobin, serum amyloid protein, serum 
glutamic oxaloacetic, transaminase thrombopoietin, and 
von Willebrand factor) exhibited a trend towards increased 
expression whereas two (tumor necrosis factor-related activa-
tion protein (CD-40 L) and interleukin-7) appeared to exhibit 
a trend towards decreased expression (Figure 8C).
Discussion
Investigation of the effects that nanomaterials may have on 
cellular function is essential for ensuring that the utilization 
of these materials in industrial or medical applications is safe. 
Although CeO
2
 nanoparticles have demonstrated excellent 
potential for biomedical use,7,8,10 limited knowledge exists 
concerning their potential systemic toxicity. The primary 
finding of this investigation was that intratracheal instillation 
of CeO
2
 nanoparticles (Figure 1) results in increased liver 
ceria levels (Figure 2), and that these changes in liver ceria are 
associated with evidence of liver pathology (Figures 3 and 4), 
decreases in liver weight (Table 1), and alterations in blood 
chemistry (Table 2). Consistent with other reports examining 
CeO
2
,15 titanium dioxide,16 silica,17 and copper18 nanopar-
ticles, our data suggest it is possible that CeO
2
 nanoparticles 
are capable of translocating from the lung to the liver via the 
circulation.
The histopathological appearance of the liver fol-
lowing CeO
2
 nanoparticle instillation is consistent with 
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Figure 2 Concentration of cerium in liver after intratracheal instillation of cerium 
oxide nanoparticles.
Note: *Significantly different from the vehicle control (P , 0.05).
Table 1 Alterations in absolute organ wet weight 28 days after intratracheal instillation of cerium oxide nanoparticles
Organ weight (g) Saline control  
(n = 7)
CeO2 1.0 mg/kg  
(n = 7)
CeO2 3.5 mg/kg  
(n = 7)
CeO2 7.0 mg/kg 
(n = 7)
Heart (g)  1.52 ± 0.15  1.35 ± 0.05  1.27 ± 0.07  1.23 ± 0.05
Liver (g) 14.55 ± 0.27 14.30 ± 1.04 14.78 ± 0.57 12.50 ± 0.54*
Kidney (g)  2.67 ± 0.31  2.55 ± 0.21  2.54 ± 0.33  2.43 ± 0.31
Spleen (g)  0.58 ± 0.06  0.65 ± 0.10  0.56 ± 0.08  0.64 ± 0.04
Note: *Significantly different from vehicle control (P , 0.05).
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the  possibility that ceria can induce several different 
pathological alterations, including hydropic degeneration 
of hepatocytes, enlargement of hepatocytes, dilatation of 
the sinusoids, and nuclear enlargement (Figures 3 and 4). 
There was no evidence of granuloma, portal inflammation, 
fibrosis, or bile duct abnormalities, except for the presence 
of some local inflammation of the lobules in some 
animals.
Because the liver is the major organ for biotransforma-
tion of toxins, it may be the first organ to be exposed to 
nanoparticles that are able to enter into the circulation. It 
is thought that hydropic degeneration can be caused by 
hypoxia,19 ischemia,20 or the treatment of hepatocytes with 
endotoxins21 or chemicals.22 Consistent with our findings, 
this response has also been observed following exposure 
to other toxic materials, including copper nanoparticles23 
and carbon tetrachloride,24 or following the inhalation of 
anesthetics such as sevofulrane and desflurane.25 How 
exposure to CeO
2
 nanoparticles may induce hydropic 
degeneration or if these changes are reversible is currently 
unclear. Sinusoidal dilatation is the increased gap between 
the hepatic cords in the hepatic lobule that has also been 
observed in aluminum-induced hepatic toxicity,26 carbon 
tetrachloride-induced hepatic toxicity,27 and ischemia,28 
as well as with the organophosphate insecticide, methi-
dathion.29 In addition, we also noted the accumulation of 
granular material inside the hepatocytes which appeared 
to be dose-dependent and perhaps related to reduction of 
liver weight (Table 1).
Table 2 Changes in serum biochemical parameters (A) and lipid profile (B) 28 days after the intratracheal instillation of cerium oxide 
nanoparticles
Analyte Saline control  
(n = 7)
CeO2 1.0 mg/kg  
(n = 7)
CeO2 3.5 mg/kg  
(n = 7)
CeO2 7.0 mg/kg 
(n = 7)
A
Glucose 186.4 ± 25.7 208 ± 43.0 197.6 ± 40.2 231 ± 93.5
ALP 276.1 ± 53.7 263 ± 55.4 242 ± 35.3 222.23 ± 81.9
ALT 58.3 ± 10.7 83.4 ± 28.5 88.3 ± 31.4 130.5 ± 94.5*
Amylase 974.7 ± 97.4 1055.1 ± 124.2 991.4 ± 116 908.4 ± 277.0
Total protein 6.0 ± 0.1 5.9 ± 0.6 6.2 ± 0.5 5.4 ± 1.3
Albumin 4.2 ± 0.2 4.1 ± 0.5 4.5 ± 0.4 3.5 ± 1.1*
Globulin 1.8 ± 0.2 1.8 ± 0.2 2.0 ± 0.2 1.8 ± 0.2
ALB-GLOB ratio 2.3 ± 0.3 2.3 ± 0.3 2.2 ± 0.3 1.9 ± 0.6
BUN 15.4 ± 1.1 15 ± 3.1 15.7 ± 1.9 14.4 ± 4.2
Creatinine 0.3 ± 0.1 0.27 ± 0.1 0.23 ± 0.1 0.28 ± 0.1
Ca2+ 11.4 ± 0.7 10.7 ± 1.3 11.5 ± 1.1 10.4 ± 2.4
Phosphorus 8.6 ± 0.9 7.9 ± 1.2 8.7 ± 1.0 8.2 ± 1.9
Na+ 142.3 ± 0.9 138 ± 10.7 138.1 ± 10.7 132.1 ± 16.3
K+ 5.5 ± 0.4 6.0 ± 0.5 6.5 ± 0.6 5.8 ± 0.9
Na+-K+ ratio 25.8 ± 2.0 22.9 ± 1.7* 21.2 ± 1.4* 22.8 ± 2.5*
B
Total cholesterol 100.7 ± 1.9 100 ± 0 100 ± 0 103.1 ± 8.3
Triglycerides 143 ± 53 109.6 ± 50.9 190.3 ± 83.7 93.1 ± 22.3*
HDL 21 ± 6.0 19.4 ± 5.4 20 ± 6.4 19 ± 5.1
Note: *Significantly different from the vehicle control (P , 0.05).
Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; ALB-GLOB ratio, albumin to globulin ratio; BUN, blood urea nitrogen; Ca, calcium; Na, sodium; 
K, potassium; Na-K ratio, sodium to potassium ratio; HDL, high density lipoproteins.
A B
C D
100 µm
Figure 3 Cerium oxide nanoparticle exposure alters histopathological architecture 
of the liver. (A) Saline control (400×), (B) CeO2 at 1.0 mg/kg (400×), (C) CeO2 
3.5 mg/kg (400×), and (D) CeO2 7.0 mg/kg (400×). Note evidence of hydropic 
degeneration (arrow) with CeO2 instillation.
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A B
C D
100 µm
Figure 5 Cerium oxide nanoparticle exposure has no effect on the histological 
appearance of the kidney. (A) Saline control (400×), (B) CeO2 at 1.0 mg/kg (400×), 
(C) CeO2 3.5 mg/kg (400×), and (D) CeO2 7.0 mg/kg (400×).
A B
C D
100 µm
Figure 6 Cerium oxide nanoparticle exposure has no effect on the histological 
appearance of the spleen. (A) Saline control (400×), (B) CeO2 at 1.0 mg/kg (400×), 
(C) CeO2 3.5 mg/kg (400×), and (D) CeO2 7.0 mg/kg (400×).
A B
C D
100 µm
Figure 7 Cerium oxide nanoparticle exposure has no effect on histological 
appearance of heart. (A) saline control (400×), (B) CeO2 at 1.0 mg/kg (400×), 
(C) CeO2 3.5 mg/kg (400×), and (D) CeO2 7.0 mg/kg (400×).
A B C
100 µm
Focal inflammation Arrow: sinusoidal dilatation Arrow: binucleation
Figure 4 Histopathological alterations with the CeO2 nanoparticle exposure (7.0 mg/kg) include (A) focal inflammation, (B) sinusoidal dilatation, and (C) binucleation of 
the hepatocyte (400×).
Our serum biochemical profile data suggest that CeO
2
 
nanoparticle instillation in the rat may be associated with an 
elevation of alanine aminotransferase and reduction in albu-
min (Table 2). It is well established that hepatocyte damage 
is associated with the release of liver enzymes into the cir-
culation and reduced albumin levels.26 In addition to changes 
in the level of circulating liver enzymes, CeO
2
 nanoparticle 
instillation also appears to decrease the sodium-potassium 
ratio and the amount of triglycerides (Table 2).
Similar to other work examining other types of nano-
particles,30,31 we observed a trend towards an increasing 
serum concentration of haptoglobin (16%), serum amyloid 
P protein (24%), and von Willebrand factor (33%) following 
exposure to CeO
2
 nanoparticles. Consistent with our histo-
pathological findings, and the possibility of hepatic injury, 
we also found evidence that CeO
2
 nanoparticle instillation 
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Figure 8 Cerium oxide nanoparticles exposure results in alterations in the expression of serum protein biomarkers.
was associated with a trend toward increases in the amount 
of serum thrombopoietin, fibroblast growth factor, serum 
glutamic oxaloacetic transaminase, and transaminase throm-
bopoietin (Figure 4). Elevation in these serum biomarkers is 
thought to be highly correlated with acute hepatic injury.22,32 
Taken together, these data suggest that ceria deposition may 
be associated with liver damage. Given our findings that 
CeO
2
 nanoparticle instillation, at least at the levels used 
in the current study, does not induce appreciable damage 
to the heart, kidney, or spleen. It is possible that the liver, 
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by acting to clear CeO
2
 nanoparticles from the circulation, 
is  functioning to prevent additional secondary or tertiary 
pathological changes elsewhere.
Conclusion
In summary, our data suggest that intratracheal instillation of 
CeO
2
 nanoparticles may be associated with  hepatotoxicity. 
The toxicity induced by CeO
2
 nanoparticles appears to be 
dose-dependent, because the rats instilled with 7.0 mg/kg 
body weight of CeO
2
 nanoparticles exhibited the  greatest 
 evidence of toxicological response. The  toxicological 
response appears to be limited to the liver and may 
occur through extrapulmonary translocation of the CeO
2
 
 nanoparticles into the systemic circulation. Given these 
findings, additional research to evaluate the health effects 
of CeO
2
 nanoparticles is likely warranted.
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